MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.bbmt.2017.11.019

Медицинская библиотека · Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2017

Outcomes after Allogeneic Transplant in Patients with Wiskott-Aldrich Syndrome.

Ngwube Alexander, Hanson I Celine, Orange Jordan, Rider Nicholas L, Seeborg Filiz, Shearer William, Noroski Lenora, Nicholas Sarah, Forbes Lisa, Leung Kathryn, Sasa Ghadir, Naik Swati, Hegde Meenakshi, Omer Bilal, Ahmed Nabil, Allen Carl, Gottschalk Stephen, Wu Meng-Fen, Liu Hao, Brenner Malcolm, Heslop Helen, Krance Robert, Martinez Caridad

Клиническое исследованиеСтатьяПеревод в очереди

Аннотация

Wiskott-Aldrich syndrome (WAS) is a rare X-linked disorder characterized by a triad of immunodeficiency, eczema, and thrombocytopenia. Currently, hematopoietic stem cell transplantation (HSCT) is the most reliable curative treatment with excellent results for patients with HLA-matched family or unrelated donors. However, even after fully myeloablative preparative regimens, mixed donor chimerism is a potential concern. We performed a retrospective chart review of 12 children who underwent allogeneic HSCT for WAS to report our experience. The median age at transplant was 10.5 months (range, 3 to 39). The median nucleated cell dose from the marrow was 4.55 × 109/kg (range, .3 to 7.9). The median times to neutrophil and platelet engraftment were 19 days (range, 13 to 27) and 18.5 days (range, 12 to 31), respectively. The rate of overall survival was 92% with median follow-up of 67 months (range, 3 to 146). Two patients developed grade IV acute graft-versus-host disease, and 1 died on day +99. Five of 12 patient's (42%) had mixed donor chimerism (range, 12% to 85%) at day +180. None of the pretransplant patient parameters was predictive of mixed chimerism. Nonetheless, of these 5 patients, 2 had normalization of the platelet count despite the mixed chimerism, 2 had full donor chimerism after receiving a second transplant with the same donor, and 1 remains transfusion dependent awaiting a second transplant. Hence, even with a significant rate of mixed chimerism, HSCT provides substantial benefit to WAS patients, with excellent overall survival.

Для цитирования: Ngwube Alexander, Hanson I Celine, Orange Jordan, Rider Nicholas L, Seeborg Filiz, Shearer William, Noroski Lenora, Nicholas Sarah, Forbes Lisa, Leung Kathryn, Sasa Ghadir, Naik Swati, Hegde Meenakshi, Omer Bilal, Ahmed Nabil, Allen Carl, Gottschalk Stephen, Wu Meng-Fen, Liu Hao, Brenner Malcolm, Heslop Helen, Krance Robert, Martinez Caridad. Outcomes after Allogeneic Transplant in Patients with Wiskott-Aldrich Syndrome.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2017. DOI: 10.1016/j.bbmt.2017.11.019.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.